Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

NCT ID: NCT01126697

Last Updated: 2018-06-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2017-12-31

Brief Summary

The study will include 120 participants aged 8 and up with Duchenne, Becker, or autosomal recessive limb-girdle (specifically: LGMD 2C-2F and 2I) muscular dystrophies that have no clinical cardiac symptoms. Participants will be randomized to one of four arms: Arm 1 CoQ10 alone, Arm 2 Lisinopril alone, Arm 3 CoQ10 and Lisinopril or Arm 4 No study medication. Randomization will be stratified by ambulatory status and corticosteroid use. The primary outcome for the study is the myocardial performance index (MPI), measured by standard Doppler echocardiography. The study will last 24 months with visits at Months 0.5,1.5, 6, 12, 18 and 24.

Following completion of the Clinical Trial of Coenzyme Q10 and Lisinopril, participants will be offered participation in a companion protocol: PITT1215 A Natural History Companion Study to PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies. The objective of this study is to evaluate the longitudinal natural history of DMD, BMD, and LGMD2I and to evaluate the effects of Coenzyme Q10 and/or Lisinopril on prevention of cardiac dysfunction in these disorders.This will be an 18-month longitudinal natural history study designed to accompany the Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies.

Conditions

Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular Dystrophy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Enhanced standard of care

Group Type: NO_INTERVENTION

No interventions assigned to this group

Lisinopril

Group Type: ACTIVE_COMPARATOR

Coenzyme Q10 and Lisinopril

Intervention Type: DRUG

Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Coenzyme Q10

Group Type: ACTIVE_COMPARATOR

Coenzyme Q10 and Lisinopril

Intervention Type: DRUG

Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Coenzyme Q10 and Lisinopril

Group Type: ACTIVE_COMPARATOR

Coenzyme Q10 and Lisinopril

Intervention Type: DRUG

Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Interventions

Coenzyme Q10 and Lisinopril

Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 8 years of age or older
• Confirmed genetic diagnosis of Duchenne, Becker, or Limb Girdle muscular dystrophy
• Beta-blocker naïve
• Screening Doppler echocardiographic MPI measurement greater than or equal to 0.40 for the highest MPI value (spectral and tissue) or circumferential strain measured by STE that is less negative than or equal to - 23
• Normal left ventricular fractional shortening (≥28%) and no clinical cardiac symptoms
• Has not participated in other therapeutic research protocol within the last 6 months prior to screening
• Ability to swallow tablets

Exclusion Criteria

• Spine curvature greater than 30% (based on the x-ray performed at screening)
• History of significant concomitant illness or significant impairment of renal or hepatic function
• History of hypersensitivity to ACE inhibitors
• History of idiopathic or hereditary angioedema or a history of angioedema with prior ACE inhibitor use
• Use of carnitine, creatine, glutamine, or any herbal medicines (this would not include herbal teas unless they are consumed daily with intended medicinal effect) in the 3-months prior to enrollment
• CoQ10 and/or ACE inhibitor use for a duration greater than 6 months
• CoQ10 and/or ACE inhibitor use in the 3-months prior to enrollment
• CoQ10 serum level of 2.5 ug/ml or higher
• Investigator assessment of inability to comply with protocol

• Minimum Eligible Age: 8 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

United States Department of Defense

FED

Sponsor Role: collaborator

Cooperative International Neuromuscular Research Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Children's National Medical Center

Washington D.C., District of Columbia, United States

Lurie Children's Hospital

Chicago, Illinois, United States

Carolinas Medical Center

Charlotte, North Carolina, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

University of Tennessee

Memphis, Tennessee, United States

Alberta Children's Hospital

Calgary, Alberta, Canada

National Center of Neurology and Psychiatry

Tokyo, , Japan

Countries

United States; Canada; Japan

Related Links

http://www.cinrgresearch.org

CINRG Network Website

Other Identifiers

PITT0908

Identifier Type: -

Identifier Source: org_study_id